Letter

Patients' interests: paramount in randomised trials

BMJ 2004; 330 doi: 10.1136/bmj.330.7481.44-a (Published 30 December 2004)
Cite this as: BMJ 2004;330:44.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Tony Stevens, consumer liaison lead (t.stevens@ncrn.org.uk),
  2. Roger Wilson, chair, National Cancer Research Institute Consumer Liaison Group
  1. National Cancer Research Network, Cookridge Hospital, Leeds LS16 6QB

    EDITOR—Patients and the public recognise the need for large randomised trials. Trialists must also recognise the responsibilities they owe to their study participants. There has been some debate on whether these responsibilities are always fully discharged.

    The early stopping of the MA17 trial, with data released to the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular